| MERGANCOVA, Jana, Anna LIEROVA, Oldřich COUFAL, Jan ZATECKY, Bohuslav MELICHAR, Ilona ZEDNIKOVA, Jindriska MERGANCOVA, Anna JESENKOVA, Karel STASTNY, Jiri GATEK, Otakar KUBALA, Jiri PROKOP, Daniel DYTTERT, Marian KARABA, Ivana SCHWARZBACHEROVA, Anna HUMENANSKA, Jindrich SUK, Michal VALENTA, Vladimir MOUCHA, Lukas SAKRA, Ales HLAVKA, Maria HACOVA, Radovan VOJTISEK, Marek SOCHOR, Tomas JIRASEK, Michaela ZABOJNIKOVA, Martina ZEMANOVA, Katarina MACHALEKOVA, Dominika RUSNAKOVA, Eva KUDELOVA a Marek SMOLAR. Radiation-associated angiosarcoma of the breast: An international multicenter analysis. SURGICAL ONCOLOGY-OXFORD. OXFORD: ELSEVIER SCI LTD, 2022, roč. 41, May 2022, s. 1-8. ISSN 0960-7404. Dostupné z: https://dx.doi.org/10.1016/j.suronc.2022.101726. |
Další formáty:
BibTeX
LaTeX
RIS
@article{2250039,
author = {Mergancova, Jana and Lierova, Anna and Coufal, Oldřich and Zatecky, Jan and Melichar, Bohuslav and Zednikova, Ilona and Mergancova, Jindriska and Jesenkova, Anna and Stastny, Karel and Gatek, Jiri and Kubala, Otakar and Prokop, Jiri and Dyttert, Daniel and Karaba, Marian and Schwarzbacherova, Ivana and Humenanska, Anna and Suk, Jindrich and Valenta, Michal and Moucha, Vladimir and Sakra, Lukas and Hlavka, Ales and Hacova, Maria and Vojtisek, Radovan and Sochor, Marek and Jirasek, Tomas and Zabojnikova, Michaela and Zemanova, Martina and Machalekova, Katarina and Rusnakova, Dominika and Kudelova, Eva and Smolar, Marek},
article_location = {OXFORD},
article_number = {May 2022},
doi = {http://dx.doi.org/10.1016/j.suronc.2022.101726},
keywords = {Radiation; Angiosarcoma; Breast; Multicenter study},
language = {eng},
issn = {0960-7404},
journal = {SURGICAL ONCOLOGY-OXFORD},
title = {Radiation-associated angiosarcoma of the breast: An international multicenter analysis},
url = {https://www.sciencedirect.com/science/article/pii/S0960740422000196?via%3Dihub},
volume = {41},
year = {2022}
}
TY - JOUR
ID - 2250039
AU - Mergancova, Jana - Lierova, Anna - Coufal, Oldřich - Zatecky, Jan - Melichar, Bohuslav - Zednikova, Ilona - Mergancova, Jindriska - Jesenkova, Anna - Stastny, Karel - Gatek, Jiri - Kubala, Otakar - Prokop, Jiri - Dyttert, Daniel - Karaba, Marian - Schwarzbacherova, Ivana - Humenanska, Anna - Suk, Jindrich - Valenta, Michal - Moucha, Vladimir - Sakra, Lukas - Hlavka, Ales - Hacova, Maria - Vojtisek, Radovan - Sochor, Marek - Jirasek, Tomas - Zabojnikova, Michaela - Zemanova, Martina - Machalekova, Katarina - Rusnakova, Dominika - Kudelova, Eva - Smolar, Marek
PY - 2022
TI - Radiation-associated angiosarcoma of the breast: An international multicenter analysis
JF - SURGICAL ONCOLOGY-OXFORD
VL - 41
IS - May 2022
SP - 1-8
EP - 1-8
PB - ELSEVIER SCI LTD
SN - 09607404
KW - Radiation
KW - Angiosarcoma
KW - Breast
KW - Multicenter study
UR - https://www.sciencedirect.com/science/article/pii/S0960740422000196?via%3Dihub
N2 - Introduction: Radiation-associated angiosarcoma (RAAS) is a rare and serious complication of breast irradiation. Due to the rarity of the condition, clinical experience is limited and publications on this topic include only retrospective studies or case reports.Materials and methods: All patients diagnosed with RAAS between January 2000 and December 2017 in twelve centers across the Czech Republic and Slovakia were evaluated.Results: Data of 53 patients were analyzed. The median age at diagnosis was 72 (range 44-89) years. The median latency period between irradiation and diagnosis of RAAS was 78 (range 36-172) months. The median radiation dose was 57.6 (range 34-66) Gy. The whole breast radiation therapy with radiation boost to the tumor bed was the most common radiotherapy regimen. Total mastectomy due to RAAS was performed in 43 patients (81%), radical excision in 8 (15%); 2 patients were not surgically treated due to unresectable disease. Adjuvant chemotherapy followed surgical therapy of RAAS in 18 patients, 3 patients underwent adjuvant radiotherapy. The local recurrence rate of RAAS was 43% and the median time from surgery to the onset of recurrence was 7.5 months (range 3-66 months). The 3-year survival rate was 56%, the 5-year survival rate was only 33%. 46% of patients died during the follow-up period.Conclusion: The present data demonstrate that RAAS is a rare condition with high local recurrence rate (43%) and mortality (the 5-year survival rate was 33%.). Early diagnosis of RAAS based on biopsy is crucial for treatment with radical intent. Surgery with negative margins constitutes the most important part of the therapy; the role of adjuvant chemotherapy and radiotherapy is still unclear.
ER -
MERGANCOVA, Jana, Anna LIEROVA, Oldřich COUFAL, Jan ZATECKY, Bohuslav MELICHAR, Ilona ZEDNIKOVA, Jindriska MERGANCOVA, Anna JESENKOVA, Karel STASTNY, Jiri GATEK, Otakar KUBALA, Jiri PROKOP, Daniel DYTTERT, Marian KARABA, Ivana SCHWARZBACHEROVA, Anna HUMENANSKA, Jindrich SUK, Michal VALENTA, Vladimir MOUCHA, Lukas SAKRA, Ales HLAVKA, Maria HACOVA, Radovan VOJTISEK, Marek SOCHOR, Tomas JIRASEK, Michaela ZABOJNIKOVA, Martina ZEMANOVA, Katarina MACHALEKOVA, Dominika RUSNAKOVA, Eva KUDELOVA a Marek SMOLAR. Radiation-associated angiosarcoma of the breast: An international multicenter analysis. \textit{SURGICAL ONCOLOGY-OXFORD}. OXFORD: ELSEVIER SCI LTD, 2022, roč.~41, May 2022, s.~1-8. ISSN~0960-7404. Dostupné z: https://dx.doi.org/10.1016/j.suronc.2022.101726.
|
